A recent study published in The Lancet Infectious Diseases announced transformative results from a randomized clinical trial focusing on patients with low-risk Staphylococcus aureus bloodstream infections. The trial conducted across 31 hospitals in Germany, France, the Netherlands, and Spain, showed that an early switch from intravenous (IV) to oral antibiotic therapy was as effective as continuing the course of IV therapy. This stands to dramatically change hospital protocols and significantly reduce hospitalization durations. The study encompassed 213 patients who were primarily elderly males. They were administered IV antibiotic therapy for 5 to 7-days before being randomly divided into two groups – the patients who continued with IV therapy versus those who transitioned to oral therapy. The treatment course lasted for a total of 14 days.
The primary goal was to investigate the occurrence rate of any complications connected to Staphylococcus aureus bloodstream infections within a 90-day timeframe. The findings revealed no stark contrast between the two groups, proving the non-inferiority of the oral therapy model. Hospital stays were notably shorter in the group that shifted to oral antibiotics, a median 12 days versus 16 days for the IV therapy cohort. The investigators corroborated that provided adequate clinical assessment and monitoring of complications, an early switch to oral therapy is recommended for such patients. This potentially leads to simpler treatment protocols and quicker hospital discharges.